Affinity Asset Advisors, LLC Apellis Pharmaceuticals, Inc. Transaction History

Affinity Asset Advisors, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$55.39 - $72.47 $4.99 Million - $6.52 Million	90,000 Added 120.0%	165,000 $9.7 Million
Q4 2023 Feb 13, 2024	BUY	$37.14 - $64.82 $1.3 Million - $2.27 Million	35,000 Added 87.5%	75,000 $4.49 Million
Q3 2023 Nov 14, 2023	BUY	$23.65 - $89.22 $709,500 - $2.68 Million	30,000 Added 300.0%	40,000 $1.52 Million
Q2 2023 Aug 14, 2023	SELL	$76.68 - $93.31 $1.92 Million - $2.33 Million	-25,000 Reduced 71.43%	10,000 $911,000
Q1 2023 May 15, 2023	BUY	$46.59 - $66.96 $1.63 Million - $2.34 Million	35,000 New	35,000 $2.31 Million
Q3 2021 Nov 12, 2021	SELL	$31.4 - $69.84 $314,000 - $698,400	-10,000 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$40.9 - $64.9 $409,000 - $649,000	10,000 New	10,000 $632,000

310

113M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.29B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Affinity Asset Advisors, LLC with notifications on news.